Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Meta D3 Nano Shots is a high-potency oral liquid formulation of cholecalciferol (Vitamin D3) developed by Matins Pharma. Each unit typically contains 60,000 IU of cholecalciferol, utilizing a nano-emulsion delivery system designed to improve the solubility and absorption of this fat-soluble vitamin. Once ingested, cholecalciferol undergoes hydroxylation in the liver and kidneys to form its active metabolite, calcitriol. Calcitriol binds to the Vitamin D receptor (VDR), a nuclear transcription factor, which then modulates the expression of genes involved in calcium and phosphate homeostasis. This product is primarily used for the treatment and prevention of Vitamin D deficiency and associated bone disorders such as osteoporosis and osteomalacia.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Meta D3 Nano Shots (cholecalciferol).